Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

452 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Pralatrexate is an effective treatment for relapsed or refractory transformed mycosis fungoides: a subgroup efficacy analysis from the PROPEL study.
Foss F, Horwitz SM, Coiffier B, Bartlett N, Popplewell L, Pro B, Pinter-Brown LC, Shustov A, Furman RR, Haioun C, Koutsoukos T, O'Connor OA. Foss F, et al. Among authors: horwitz sm. Clin Lymphoma Myeloma Leuk. 2012 Aug;12(4):238-43. doi: 10.1016/j.clml.2012.01.010. Epub 2012 Apr 26. Clin Lymphoma Myeloma Leuk. 2012. PMID: 22542448 Clinical Trial.
Rituximab in lymphocyte-predominant Hodgkin disease: results of a phase 2 trial.
Ekstrand BC, Lucas JB, Horwitz SM, Fan Z, Breslin S, Hoppe RT, Natkunam Y, Bartlett NL, Horning SJ. Ekstrand BC, et al. Among authors: horwitz sm. Blood. 2003 Jun 1;101(11):4285-9. doi: 10.1182/blood-2002-08-2644. Epub 2003 Feb 13. Blood. 2003. PMID: 12586628 Free article. Clinical Trial.
Primary mediastinal large B-cell lymphoma: optimal therapy and prognostic factor analysis in 141 consecutive patients treated at Memorial Sloan Kettering from 1980 to 1999.
Hamlin PA, Portlock CS, Straus DJ, Noy A, Singer A, Horwitz SM, Oconnor OA, Yahalom J, Zelenetz AD, Moskowitz CH. Hamlin PA, et al. Among authors: horwitz sm. Br J Haematol. 2005 Sep;130(5):691-9. doi: 10.1111/j.1365-2141.2005.05661.x. Br J Haematol. 2005. PMID: 16115124 Free article.
Clinical experience with intravenous and oral formulations of the novel histone deacetylase inhibitor suberoylanilide hydroxamic acid in patients with advanced hematologic malignancies.
O'Connor OA, Heaney ML, Schwartz L, Richardson S, Willim R, MacGregor-Cortelli B, Curly T, Moskowitz C, Portlock C, Horwitz S, Zelenetz AD, Frankel S, Richon V, Marks P, Kelly WK. O'Connor OA, et al. J Clin Oncol. 2006 Jan 1;24(1):166-73. doi: 10.1200/JCO.2005.01.9679. Epub 2005 Dec 5. J Clin Oncol. 2006. PMID: 16330674
Pralatrexate, a novel class of antifol with high affinity for the reduced folate carrier-type 1, produces marked complete and durable remissions in a diversity of chemotherapy refractory cases of T-cell lymphoma.
O'Connor OA, Hamlin PA, Portlock C, Moskowitz CH, Noy A, Straus DJ, Macgregor-Cortelli B, Neylon E, Sarasohn D, Dumetrescu O, Mould DR, Fleischer M, Zelenetz AD, Sirotnak F, Horwitz S. O'Connor OA, et al. Br J Haematol. 2007 Nov;139(3):425-8. doi: 10.1111/j.1365-2141.2007.06658.x. Br J Haematol. 2007. PMID: 17910632 Free article. Clinical Trial.
Novel therapies for cutaneous T-cell lymphomas.
Horwitz SM. Horwitz SM. Clin Lymphoma Myeloma. 2008 Dec;8 Suppl 5:S187-92. doi: 10.3816/CLM.2008.s.015. Clin Lymphoma Myeloma. 2008. PMID: 19073526 Review.
A multi-institutional experience of autologous stem cell transplantation in North American patients with human T-cell lymphotropic virus type-1 adult T-cell leukemia/lymphoma suggests ineffective salvage of relapsed patients.
Phillips AA, Willim RD, Savage DG, Horwitz SM, Isola L, Zain JM, O'Connor OA. Phillips AA, et al. Among authors: horwitz sm. Leuk Lymphoma. 2009 Jun;50(6):1039-42. doi: 10.1080/10428190902887571. Leuk Lymphoma. 2009. PMID: 19373596 No abstract available.
Phase II-I-II study of two different doses and schedules of pralatrexate, a high-affinity substrate for the reduced folate carrier, in patients with relapsed or refractory lymphoma reveals marked activity in T-cell malignancies.
O'Connor OA, Horwitz S, Hamlin P, Portlock C, Moskowitz CH, Sarasohn D, Neylon E, Mastrella J, Hamelers R, Macgregor-Cortelli B, Patterson M, Seshan VE, Sirotnak F, Fleisher M, Mould DR, Saunders M, Zelenetz AD. O'Connor OA, et al. J Clin Oncol. 2009 Sep 10;27(26):4357-64. doi: 10.1200/JCO.2008.20.8470. Epub 2009 Aug 3. J Clin Oncol. 2009. PMID: 19652067 Free PMC article. Clinical Trial.
452 results